Search This Blog

Thursday, April 27, 2023

Oral sex is fueling an ‘epidemic’ of throat cancer

 Oral sex is the X-rated culprit behind a wave of throat cancer cropping up in the US, fueling a so-called “epidemic.”

According to Hisham Mehanna, a professor at the Institute of Cancer and Genomic Sciences at the University of Birmingham, the human papillomavirus is to blame.

“For oropharyngeal cancer, the main risk factor is the number of lifetime sexual partners, especially oral sex,” he wrote for the Conversation Tuesday.

Cases of HPV-linked oropharyngeal cancer, a type of throat cancer, rose annually by 1.3% in women and 2.8% in men from 2015 to 2019, according to the American Cancer Society.

The CDC estimates that 70% of oropharyngeal cancers — which affect the tonsils, base of the tongue and back of the throat — are caused by HPV infection in the US.

Past studies have shown that multiple sexual partners could increase the risk of catching HPV and, in turn, developing mouth or throat cancer.

In 2021, researchers discovered that people with 10 or more oral sex partners were more than four times more likely to develop HPV-related mouth and throat cancers.

Digital image of person with sore throat
HPV accounts for an estimated 70% of oropharyngeal cancers, per the CDC.
Getty Images/iStockphoto

According to data from the Centers for Disease Control and Prevention, 41% of teens from 15 to 19 participate in oral sex. Young people ages 15 to 24 were responsible for nearly half of the 26 million new STD infections in 2018.

Woman getting screened on her neck in doctor's office
A rise of oropharyngeal cancers could be caused by HPV, experts say.
Getty Images

HPV is one of the most common sexually transmitted infections (STIs), affecting an estimated 42 million Americans. In fact, it’s so prevalent, according to the CDC, that “nearly all sexually active men and women get the virus at some point in their lives.”

Typically harmless — many people clear the virus on their own with no complications — the virus can lead to cervical or oropharyngeal cancers in some cases.

Man with sore throat
Symptoms include a persistent sore throat, trouble swallowing or opening the mouth, difficulty moving the tongue and lumps in the mouth, throat and neck.
Getty Images/iStockphoto

“However, a small number of people are not able to get rid of the infection, maybe due to a defect in a particular aspect of their immune system,” writes Mehanna. “In those patients, the virus is able to replicate continuously, and over time integrates at random positions into the host’s DNA, some of which can cause the host cells to become cancerous.”

A UK study discovered that the country’s female-only vaccine regimen could significantly reduce HPV-related oropharyngeal cancers. Currently, the HPV vaccine is aimed at preventing reproductive cancers, although the CDC said it does offer protection against the strains of the virus that also cause oropharyngeal cancer.

The current guidance in the US advises 11- and 12-year-olds to receive two doses of the HPV vaccine, but individuals from the ages of 9 to 26 are approved to receive it.

Yet only about 54% of adolescents had received the vaccine as of 2020.

“Over 90% of HPV-associated cancers could be prevented with the HPV vaccination, yet vaccine uptake remains suboptimal,” study author Eric Adjei Boakye said in a statement. His research for the American Association for Cancer Research published this month revealed the lack of knowledge around HPV.

https://nypost.com/2023/04/27/oral-sex-fueling-epidemic-of-throat-cancer-doctor-warns/

Haley predicts Biden will die within 5 years if re-elected, leaving Harris president

 GOP presidential contender Nikki Haley says President Biden would likely die within five years if re-elected — warning his supporters they’d have to contend with Kamala Harris in the Oval Office.

Haley doubled-down on criticism of Biden’s decision to run again after the 80-year-old — the oldest president in the nation’s history — announced his re-election campaign Tuesday.

“I think that we can all be very clear and say with a matter of fact that if you vote for Joe Biden you really are counting on a President Harris, because the idea that he would make it until 86 years old is not something that I think is likely,” Haley, 51, told Fox News.

Haley has previously argued candidates over 75 should take cognitive tests — a move that would also affect current GOP front-runner Donald Trump, 76.

Biden, however, doesn’t see his age as an issue despite attacks from the right, declaring he’s his party’s best candidate against Trump.

“I can’t even say — I guess, how old I am. I can’t even say the number,” Biden told reporters Tuesday.

“It doesn’t — it doesn’t register with me. …I took a hard look at it before I decided to run. And I feel good.” he said.

Nikki Haley is pictured in a Fox News interview.
Nikki Haley said Thursday President Biden would likely die within five years if re-elected.
Fox News
Joe Biden is pictured speaking to a crowd.
Joe Biden, who is currently the oldest president to serve office, assured Americans that his age was not an issue.
AP

Though Biden is trying to make his age a nonissue, critics have pointed to gaffes during his presidency as a sign of declining mental health.

On Tuesday, for example, he incorrectly said his grandfather died two weeks before Biden was born at the same hospital. Instead, his father’s father, Joseph H. Biden, died in 1941 in Baltimore’s Johns Hopkins Hospital — more than a year before Biden was born at a Scranton, Pa., hospital.

Concern about Biden’s mental fitness peaked last September when he asked “Where’s Jackie?” and searched for the late Rep. Jackie Walorski (R-Ind.) at an event — despite publicly mourning her death in a car crash and calling her family to offer his condolences in August.

Haley is pictured at a campaign event.
Haley has called for cognitive tests on all candidates over the age of 75.
Getty Images
Haley has been among the many Republicans calling attention to Biden’s gaffes, touting herself as part of a “new generation” of US leadership.

The former American ambassador to the United Nations, however, continues to trail in the polls behind Trump and Florida Gov. Ron DeSantis, who has yet to declare his intent to run in 2024.

The oldest US president upon leaving office was Ronald Reagan, who was 77 when he completed his second term in January 1989. Biden will now have that record whether or not he wins re-election.

https://nypost.com/2023/04/27/nikki-haley-predicts-biden-will-die-within-five-years-if-re-elected-leaving-kamala-harris-president/

Amgen 1st quarter profit falls as costs rise, sales up 2%

 Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.

Amgen reported revenue of $6.11 billion for the quarter, down 2% from a year earlier, but close to analysts' estimates of $6.17 billion, according to Refinitiv data.

Product sales by volume grew 14% from a year earlier, but net selling prices fell 5%, while foreign exchange rates and other factors also limited sales revenue gains, Amgen said.

Adjusted earnings per share decreased to $3.98 from $4.25 a year ago, but came in ahead of analysts' forecast of $3.85.

Amgen is seeing prescription trends return to prepandemic levels and "demand for medicines is resilient despite current macroeconomic challenges," Amgen Chief Executive Robert Bradway said on a conference call with investors.

Amgen shares, which rose by less than 1% in regular trading, were down 2.3% at $234.83 after hours.

The company said first-quarter sales of cholesterol drug Repatha rose 18% from a year earlier to a record $388 million, while sales of migraine drug Aimovig fell 32%, driven by lower prices.

Sales of psoriasis drug Otezla fell 13% and arthritis drug Enbrel saw sales drop 33%, both due in part to lower net selling prices, Amgen said.

"Misses in core assets like Enbrel fail to provide confidence needed when commercial launches are faltering," BMO Capital Markets analyst Evan Seigerman said in a research note.

Operating expenses for the quarter increased 6%, research and development costs rose 12% and Amgen said its tax rate rose 5.6 percentage points, primarily due to a Puerto Rico tax law change.

The California-based biotechnology company slightly increased its forecast for full-year 2023 revenue to range of $26.2 billion to $27.3 billion, from the previous view of $26 billion to $27.2 billion, excluding the impact of its pending acquisition of Horizon Therapeutics Plc.

TWITTER FILES: WHO Stealth-Edited Vaccine Info To Help Twitter Censor Tucker Carlson

 by Paul Thacker, former lead investigator for Sen. Chuck Grassley, via The DisInformation Chronicle (emphasis ours),

In a revisit to his famed critique of the media “Manufacturing Consent,” MIT’s Noam Chomsky explained in a 2018 interview that money and elites shape and censor the news, ensuring journalistic complicity in protecting corporations and those in power.

“The myth is that the media are independent, adversarial, courageous, struggling against power,” Chomsky said. “That’s actually true of some. There are often very fine reporters, correspondents. In fact, the media does a fine job, but within a framework that determines what to discuss, not to discuss.”

Much of this framework was exposed in a blistering account by a Columbia Journalism Review investigation that documented years of faulty reporting and journalistic failures in coverage of Trump by media outlets including the New York Times and Washington Post—many times in articles that later won journalism prizes. One of the few Americans to challenge the official framework of acceptable narratives was a controversial and polarizing Fox News TV talking head, hated by the mainstream reporters for daring to throw darts at liberal pieties.

Nonetheless, the majority of reporters have shrugged aside their colleagues’ reporting fiascoes and the damage done to their own reputations, and continue to blame most failures in journalism on one person: Tucker Carlson.

So it was not surprising that reporters began a week-long celebration this Monday when Fox fired Tucker. But years before Fox canned him, Twitter Files show that the bird company sought to clip Tucker’s wings when he reported that the World Health Organization (WHO) did not recommend that children get the COVID-19 vaccine.

When Tucker’s June 2021 report on the WHO’s vaccine recommendations hit Twitter, the WHO stealth edited their COVID vaccine page to remove language Tucker cited in his op-ed. The following day, Twitter officials began discussing Tucker’s essay and how to limit its impact without calling attention to Tucker and creating “political risks” for Twitter by directly censoring Fox News.

“Given that this article’s narrative is related to ‘big tech censorship’, I want to be mindful that taking action at the URL level could lead to this particular article gaining more traction rather than mitigating the harm,” emailed one Twitter executive.

Back and forth emails find Twitter officials scrambling to control vaccine information and limit damage to the WHO. According to a previously reported Twitter File, Twitter began helping their client Johnson and Johnson market the pharma company’s COVID vaccine in early 2021 while simultaneously removing tweets for what they called vaccine “misinformation.” In the end, Twitter apparently chose to ignore Tucker’s op-ed itself and annotate tweets for “vaccine misinformation” if the tweet were to “explicitly advance the claims in the op-ed itself.”

The Twitter employee who first brought attention to Tucker’s op-ed was policy communications specialist, Elizabeth Busby. Busby joined Twitter in 2020 after leaving the Senate, where she was deputy national press secretary to Senate Majority Leader Chuck Schumer, a frequent critic of Tucker Carlson. Busby’s work history includes a stint at SKDKnickerbocker, a PR and lobby shop closely aligned with the Democratic party. Busby now leads “trust and safety communications” at Twitter.

A peek behind the paywall...

Shortly after countries began authorizing COVID vaccines, the WHO published an evaluation of vaccine safety and efficacy on April 8, 2021. The guidance evaluated four vaccines: AstraZenca/Oxford, Johnson and Johnson, Moderna, and Pfizer/BionTech. At the time, the WHO advised people to take whichever vaccine was available, stating that the COVID-19 vaccines were safe and effective for most people 18 years and older.

For children, the WHO advised against COVID vaccines:

Children should not be vaccinated for the moment.

There is not yet enough evidence on the use of vaccines against COVID-19 in children to make recommendations for children to be vaccinated against COVID-19. Children and adolescents tend to have milder disease compared to adults. However, children should continue to have the recommended childhood vaccines.

Months later, on June 23, 2021, Tucker Carlson wrote an essay claiming that key pieces of pandemic medical advice from the WHO have been proven false and cost lives, and that Big Tech has been complicit in promoting this misinformation.

Bureaucrats at the WHO published new vaccine guidance. Here’s what it says: children should not take the coronavirus vaccine. Why? The drugs are too dangerous. There's not nearly enough data to understand the long-term effects or to show that the benefits are worth the risk that they bring. This is terrible news, of course, for the pharmaceutical industry. Big Pharma has been planning to test the vaccine on six-month-olds.

While some of the language in Tucker’s piece could be viewed as inflammatory—the WHO did not say the vaccines were “dangerous”—independent experts were also advising that children not receive the COVID vaccines, as rare but serious adverse events were not studied.

Writing in the Hill, Harvard’s Martin Kulldorff and Stanford’s Jay Bhattacharya explained that same month in June 2021:

For younger adults and children, it is a different story, as their mortality risk is extremely low. Even a slight risk of a serious vaccine adverse reaction could tip the benefit-risk calculation, making the vaccine more harmful than beneficial. We have already observed rare problems with blood clots (J&J vaccine) and myocarditis (inflammation of the heart muscle, Pfizer and Moderna) in younger people, and additional equally serious issues might still be found.

On the same day that Tucker’s op-ed hit social media, the WHO stealth edited their webpage that evaluated COVID vaccines. Here’s a link to the version dated June 22, 2021—the day before Tucker’s essay—that advises against vaccinating

When Tucker’s article began circulating on June 23, 2021, the WHO silently replaced that text with the following.

In other instances where the WHO has updated their vaccine guidance, they note this change with a date at the top of the webpage. But no update exists for changes the WHO made the day of Tucker’s essay.

The day after the WHO stealth edited their vaccine guidance, Twitter officials began discussing Tucker’s essay, which was brought to their attention by Twitter comms specialist Elizabeth Busby, the former deputy national press secretary to Senate Majority Leader Chuck Schumer.

In her email alerting Twitter’s team, Busby notes, “Given Tucker’s visibility, we anticipate there may be some press interest regardless of the enforcement outcome.”

https://www.zerohedge.com/political/twitter-files-who-stealth-edited-vaccine-info-help-twitter-censor-tucker-carlson

Ovid interest in Takeda Phase 3 soticlestat trial

 Ovid Therapeutics Inc. (NASDAQ: OVID) reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neurology (AAN) from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The findings reaffirm soticlestat was generally safe and well tolerated. Soticlestat additionally showed an encouraging median seizure reduction in both conditions.

Ovid interest in soticlestat:

Soticlestat is a potent highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) that is currently being studied by Takeda in two, pivotal Phase 3 trials for the potential treatment of DS and LGS, both highly refractory epilepsies. Ovid maintains a significant financial interest in soticlestat, including potential milestones payments and royalties, if soticlestat receives regulatory approval and is commercialized.

https://finance.yahoo.com/news/long-term-safety-efficacy-findings-183000734.html

Bristol Sees Slight Decline with Generic Competition

 After more than 20 years of service, Bristol Myers Squibb’s CEO and chairman Giovanni Caforio will leave his post, the company announced Wednesday.

Caforio’s resignation will take effect on Nov. 1, after which he will still stay with BMS as an executive chairman for a transition period, the duration of which will be determined by the company’s board. Christopher Boerner, the company’s current chief operating officer and former chief commercialization officer, will succeed Caforio.

The changes in leadership come as BMS reports a slight 3% dip in first-quarter earnings, as compared with the same period in 2022, according to a Thursday press release.

When he takes Caforio’s seat in November, Boerner will need to contend with one of the biopharma’s biggest patent cliffs, with three of the company’s top-earning drugs set to lose exclusivity this decade. U.S. patent protections for its anti-coagulant Eliquis (apixaban) will end later this year, for example, though BMS is currently requesting an extension until 2026. In addition, PD-1 inhibitor Opdivo (nivolumab) will lose its U.S. exclusivity in 2027.

Meanwhile, the company’s multiple myeloma drug Revlimid (lenalidomide), which lost patent protection in 2022, has already seen generic competition. During its Q1 earnings call, the company attributed much of its declining revenue to generic erosion of Revlimid and foreign exchange effects. The company reported 16% lower earnings outside of the U.S., bringing in $3.3 billion in the first quarter of 2023.

Pipeline Updates

BMS’ U.S. market grew, however, with $8 billion in revenues, up 4% from the same period in 2022, according to the earnings presentation. Sales from Opdivo and Eliquis, as well as its new product portfolio including Opdualag (nivolumab and relatlimab), Abecma (idecabtagene vicleucel) and Reblozyl (luspatercept), accounted for the majority of this growth.

During the earnings call, BMS representatives estimated the company would make between $10 billion and $13 billion in risk-adjusted sales by 2025 from these products. This also includes its plaque psoriasis drug Sotyktu (deucravacitinib) and heart medicine Camzyos (mavacamten).

By 2030, BMS expects to make more at least $25 billion in non-risk-adjusted revenue from this portfolio, the representatives said. 

As for its pipeline, BMS is discontinuing the early-stage development of its investigational cereblon E3 ligase modulator iberdomide in lymphoma. The molecule works by tagging specific transcription factors for destruction, thereby restricting the growth of myeloma cells. Iberdomide is currently in Phase III studies for multiple myeloma, according to BMS’s website.

The company is also making some cuts to its pipeline. It is discontinuing a Phase I lysine specific demethylase (LSD1) inhibitor for an oncology indication and ending the Phase III development of Opdivo combined with recombinant human hyaluronidase PH20, delivered subcutaneously using an auto-injector, in adjuvant melanoma.

https://www.biospace.com/article/caforio-out-boerner-in-as-bms-sees-slight-decline-with-generic-competition-/